Access the full text.
Sign up today, get DeepDyve free for 14 days.
Andrew Eisen, K. Berry, G. Gibson (1983)
Inclusion body myositis (IBM)Neurology, 33
S. Soueidan, M. Dalakas (1993)
Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulinNeurology, 43
A. Amato, R. Barohn, C. Jackson, E. Pappert, Z. Sahenk, J. Kissel (1994)
Inclusion body myositisNeurology, 44
R. Griggs, V. Askanas, S. Dimauro, A. Engel, G. Karpati, J. Mendell, L. Rowland (1995)
Inclusion body myositis and myopathiesAnnals of Neurology, 38
Tymms Tymms, Webb Webb (1985)
Ermatomyositis and other connective tissue diseases: a review of 105 casesJ. Rhenmatol, 12
A. Amato, G. Gronseth, Kevin Callerame, K. Kagan-Hallet, W. Bryan, R. Barohn (1996)
Tomaculous neuropathy: A clinical and electrophysiological study in patients with and without 1.5‐Mb deletions in chromosome 17p<11.2Muscle & Nerve, 19
A. Emslie-Smith, A. Engel (1990)
Microvascular changes in early and advanced dermatomyositis: A quantitative studyAnnals of Neurology, 27
Brohn Brohn, Amato Amato, Sahenk Sahenk (1995)
Inclusion body myositis: explanation for poor response to therapyJ Neurology, 45
J. Mendell, Z. Sahenk, T. Gales, L. Paul (1991)
Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.Archives of neurology, 48 12
J. Kissel, J. Mendell, K. Rammohan (1986)
Microvascular deposition of complement membrane attack complex in dermatomyositis.The New England journal of medicine, 314 6
J. Mendell, J. Florence (1990)
Manual muscle testingMuscle & Nerve, 13
Amato Amato, Barohn Barohn, Jackson Jackson (1994)
Inclusion body myositis: treatment with intravenous immunoglobulinJ Neurology, 44
R. Leff, Frederick Miller, J. Hicks, D. Fraser, P. Plotz (1993)
The Treatment of Inclusion Body Myositis: A Retrospective Review and a Randomized, Prospective Trial of ImmunosuppressiveMedicine, 72
Eisen Eisen, Berry Berry, Gibson Gibson (1983)
Inclusion body myositis (IBM): myopathy or neuropathy?Neurology, 33
V. Askanas, W. Engel, R. Alvarez (1993)
Enhanced detection of Congo‐red‐positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence techniqueNeurology, 43
M. Dalakas (1991)
Polymyositis, dermatomyositis and inclusion-body myositis.The New England journal of medicine, 325 21
A. Engel, K. Arahata (1984)
Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositisAnnals of Neurology, 16
J. Joy, Shin Oh, A. Baysal (1990)
Electrophysiological spectrum of inclusion body myositisMuscle & Nerve, 13
J. Kissel, Richard Halterman, K. Rammohan, J. Mendell (1991)
The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis.Archives of neurology, 48 1
M. Botez (1992)
The neuropsychology of the cerebellum: an emerging concept.Archives of neurology, 49 12
K. Arahata, A. Engel (1984)
Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cellsAnnals of Neurology, 16
M. Joffe, L. Love, R. Leff, D. Fraser, I. Targoff, I. Targoff, J. Hicks, P. Plotz, F. Miller (1993)
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.The American journal of medicine, 94 4
Inclusion body myositis, polymyositis, and dermatomyositis are three distinct categories of inflammatory myopathy. Some authorities commented on the selective early weakness of the volar forearm muscles, quadriceps, and ankle dorsiflexors in inclusion body myositis. The most important feature distinguishing inclusion body myositis from the other two inflammatory myopathies is the lack of responsiveness to immunosuppressive treatment. Although most patients with inclusion body myosities have characteristic muscle biopsy findings, some cannot be distinguished histologically early from polymyositis. Presdicting responsiveness to mmunosuppressive medications, independent of muscle histology, would be valuable to clinicians. We retrospectively reviewed the pattern of weakness and other clinical features of 46 patients newly diagnosed with either inclusion body myositis, polymyositis, or dermatomyosities. Asymmetrical muscle weakness with prominent wrist flexor, finger flexor, and knee extensor involvement was specific for inclusion body myositis and unresponsive polymyositis. Male sex, lower creatine kinase levels, slower rate of progression, and peripheral neuropathy were also more common in inclusion body myositis and unresponsive polymyositis than in responsive polymyositis and dermatomyositis patients. Repeat muscle biopsy in 2 patients in teh unresponsive polymyositis group demonstrated histological features of inclusion body myositis. We suspect that patients with clinical features of inclusion body myositis but lacking histological confirmation may nonetheless have inclusion body myositis. Our study supports the recently proposed criteria for defintie and possible inclusion body myositis.
Annals of Neurology – Wiley
Published: Oct 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.